Lurasidone
- Generic Name
- Lurasidone
- Brand Names
- Latuda
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36N4O2S
- CAS Number
- 367514-87-2
- Unique Ingredient Identifier
- 22IC88528T
- Background
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
- Indication
Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.
- Associated Conditions
- Depression, Bipolar, Schizophrenia
- Associated Therapies
- -
Lurasidone Non-Interventional Study in Schizophrenia Patients
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-08-01
- Target Recruit Count
- 61
- Registration Number
- NCT06527885
- Locations
- 🇮🇹
ASST degli Spedali Civili di Brescia, Brescia, Italy
🇮🇹Villa Von Siebenthal, Genzano Di Roma, Italy
🇮🇹Azienda Sanitaria Azienda ospedaliero-universitaria Senese, Siena, Italy
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2726
- Registration Number
- NCT06433635
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
🇺🇸John Hopkins, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Sleep Quality, Cognitive Performance, and Computerized Cognitive Training
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Target Recruit Count
- 80
- Registration Number
- NCT06328140
- Locations
- 🇺🇸
George West Mental Health Foundation, DBA Skyland Trail, Atlanta, Georgia, United States
Chinese Longitudinal and Systematic Study of Bioplar Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 10000
- Registration Number
- NCT05480150
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-03-17
- Target Recruit Count
- 10
- Registration Number
- NCT05351736
- Locations
- 🇮🇹
S.C. Psichiatria - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Lombardy, Italy
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT05213143
- Locations
- 🇨🇳
Beijing Anding Hospital, Beijing, Beijing, China
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT05011669
- Locations
- 🇨🇳
Peking University Sixth Hospital, Beijing, Beijing, China
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd.
- Target Recruit Count
- 3192
- Registration Number
- NCT04432688
- Locations
- 🇨🇳
Brain Hospital of Hunan Province, Changsha, Hunan, China
🇨🇳Beijing Anding Hospital, Beijing, Beijing, China
🇨🇳The first specialized hospital of Harbin, Harbin, Heilongjiang, China
A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Sumitomo Pharma (Suzhou) Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT04383691
- Locations
- 🇨🇳
Tianjin Anding Hospital, Tianjin, Tianjin, China
🇨🇳Mental Health Center of Xi'an City, Xi'an, Shanxi, China
🇨🇳Shanghai Mental Health Center, Shanghai, Shanghai, China
Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2023-05-06
- Target Recruit Count
- 95
- Registration Number
- NCT04312503
- Locations
- 🇮🇹
IRCCS Ospedale Policlinico San Martino, Genova, GE, Italy
🇮🇹P.O. Gaspare Rodolico - U.O.C. di Psichiatria, Catania, CT, Italy
🇮🇹A.O.U. San Luigi Gonzaga - S.C.D.U. di Psichiatria Regione Gonzole, 10, Orbassano, TO, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.